title: Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer.
abstract: OBJECTIVE
  Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. The secondary objective was to report the safety profile after a single dose of the three formulations.
  
  
  METHODS
  Patients with advanced or metastatic cancer were enrolled into this single-center, 3-period, 6-sequence crossover study. Patients were assigned sequentially to 1 of 6 sequences in blocks of 6 to ensure that all 6 sequences have the same number of completers. A patient entering a sequence received a different galunisertib formulation as a single 150 mg dose orally during each of the 3 periods. Each period was separated from the next by a washout interval of at least 48 hours. Pharmacokinetic (PK) parameters, including area under curve (AUC) and Cmax, were computed using standard non-compartmentalized methods of analysis. For comparison of exposures between formulations, log-transformed AUC and Cmaxvalues were analyzed using a linear mixed-effects model. Safety assessments included adverse event monitoring, physical examinations, and laboratory tests.
  
  
  RESULTS
  Of the 14 patients who entered and completed the study, 13 patients were included in the final statistical analysis. AUC(0-tlast), AUC(0-48 h), and AUC(0-∞) for the RC formulations and the HSWG formulation were similar. Cmaxwas reduced by approximately 22% and tmaxwas longer by at least 1.00 h for the RCD and RCS formulations compared with the HSWG formulation. The RC formulations demonstrated a safety profile after a single dose similar to the HSWG formulation.
  
  
  CONCLUSIONS
  In this relative bioavailability study comparing galunisertib formulations after a single dose, RCD and RCS formulations had similar exposure and safety profile compared with the HSWG formulation.
authors.affiliation: Eli Lilly and Company, Erl Wood, UK.
authors.forename: Ivelina
authors.initials: I
authors.lastname: Gueorguieva
authors.affiliation: Eli Lilly and Company, Erl Wood, UK.
authors.forename: Ann
authors.initials: A
authors.lastname: Cleverly
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Durisala
authors.initials: D
authors.lastname: Desaiah
authors.affiliation: Medical Oncology, Vall d'Hebron University Hospital and Universitat Autonoma de Barcelona, Barcelona, Spain.
authors.forename: Analia
authors.initials: A
authors.lastname: Azaro
authors.affiliation: Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Seoane
authors.affiliation: Medical Oncology, Vall d'Hebron University Hospital and Universitat Autonoma de Barcelona, Barcelona, Spain.
authors.forename: Irene
authors.initials: I
authors.lastname: Braña
authors.affiliation: Medical Oncology, Vall d'Hebron University Hospital and Universitat Autonoma de Barcelona, Barcelona, Spain.
authors.forename: Elisabet
authors.initials: E
authors.lastname: Sicart
authors.affiliation: Eli Lilly and Company, Erl Wood, UK.
authors.forename: Colin
authors.initials: C
authors.lastname: Miles
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Michael M
authors.initials: MM
authors.lastname: Lahn
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Malcolm I
authors.initials: MI
authors.lastname: Mitchell
authors.affiliation: Medical Oncology, Vall d'Hebron University Hospital and Universitat Autonoma de Barcelona, Barcelona, Spain.
authors.forename: Jordi
authors.initials: J
authors.lastname: Rodon
keywords: LY2157299; adverse drug event; area under curve; biological availability; half-life; neoplasms; pharmacokinetics; transforming growth factor beta